Your browser doesn't support javascript.
loading
Characteristics and patient-reported outcomes of long-term cancer survivors after apatinib-based therapy: an online survey.
Zhang, Tingting; Meng, Chao; He, Wei; Xu, Tao; Yang, Yi; Tu, Chongqi; Zhang, Ling; Sun, Xiaofeng; Zhu, Chunrong; Dang, Xueyi; Wang, Ke; Chen, Chuan; Yan, Xiong; Xu, Huiting; Huang, Le; Jiang, Enlai; Xia, Feng; Zhou, Xinming; Zhou, Shunkai; Zang, Weidong; Li, Xifeng; Zhang, Jin; Zheng, Jiaping; Xin, Jianjun; Huang, Bin; Zhu, Guopei; Zhu, Jiexiang; Liang, Jun.
Afiliación
  • Zhang T; Department of Oncology, Peking University International Hospital, 1 Life Park Road, Life Science Park of Zhongguancun, Changping District, Beijing, 102206, China.
  • Meng C; Department of Oncology, Peking University International Hospital, 1 Life Park Road, Life Science Park of Zhongguancun, Changping District, Beijing, 102206, China.
  • He W; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Xu T; Department of Gastrointestinal Surgery, Shandong Provincial Hospital, Jinan, China.
  • Yang Y; Department of Interventional Radiology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Tu C; Department of Orthopedics, West China Hospital of Sichuan University, Chengdu, China.
  • Zhang L; Department of Hepatobiliary Surgery, Henan Cancer Hospital, Zhengzhou, China.
  • Sun X; Department of Internal Medicine, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.
  • Zhu C; Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Dang X; Department of Hepatobiliary Surgery, Shanxi Cancer hospital, Taiyuan, China.
  • Wang K; Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
  • Chen C; Department of Oncology, Army Medical Center (Daping Hospital), Chongqing, China.
  • Yan X; Department of Hepatobiliary, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Xu H; Department of Abdominal Oncology, Hubei Cancer Hospital, Wuhan, China.
  • Huang L; Department of Gastrointestinal Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
  • Jiang E; Department of General Surgery, The Second Affiliated Hospital of Army Medical University, Chongqing, China.
  • Xia F; Department of Hepatobiliary, The Southwest Hospital of AMU, Chongqing, China.
  • Zhou X; Department of Gastroenterology, Xijing Hospital, Xian, China.
  • Zhou S; Department of Thoracic Surgery, The 900 Hospital of the Joint Service Support Force of the People's Liberation Army of China, Fuzhou, China.
  • Zang W; Department of Gastrointestinal Surgery, Fujian Cancer Hospital, Fuzhou, China.
  • Li X; Department of Hepatic Surgery, The Third Affiliated Hospital of the Second Military Medical University, Shanghai, China.
  • Zhang J; Department of Hepatic Surgery, The Third Affiliated Hospital of the Second Military Medical University, Shanghai, China.
  • Zheng J; Department of Interventional Radiology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Xin J; Department of Gastrointestinal Surgery, Qingdao Central Medical Group, Qingdao, China.
  • Huang B; Department of Interventional Radiology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, China.
  • Zhu G; Department of Radiation Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Zhu J; Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
  • Liang J; Department of Oncology, Peking University International Hospital, 1 Life Park Road, Life Science Park of Zhongguancun, Changping District, Beijing, 102206, China. liangjun1959@aliyun.com.
BMC Cancer ; 24(1): 1077, 2024 Aug 31.
Article en En | MEDLINE | ID: mdl-39217302
ABSTRACT

BACKGROUND:

Data on long-term cancer survivors treated with apatinib are lacking. This study aimed to describe the characteristics of long-term cancer survivors after apatinib-based therapy, and to know about their satisfaction degree with apatinib and severity of depression and insomnia.

METHODS:

Patients with solid tumors who had received apatinib-based therapy for at least 5 years were invited to complete an online questionnaire. Characteristics of patients and treatment, knowledge of apatinib, satisfaction degree, and severity of depression and insomnia assessed by Patient Health Questionnaire-9 and Insomnia Severity Index were collected.

RESULTS:

Between December 8, 2023 and March 1, 2024, a total of 436 patients completed the online questionnaire. Most patients were satisfied with the efficacy (96.6%) and safety (93.1%) of apatinib, were willing to continue apatinib treatment (99.5%), and would recommend apatinib to other patients (93.3%). Continuous apatinib treatment resulted in significant negative impact on daily life, work, or study in only two (0.5%) patients. Almost all patients currently had no or mild depression (97.0%) and insomnia (97.9%) problems. The most common patient-reported adverse events were hand-foot syndrome (21.3%) and hypertension (18.3%).

CONCLUSIONS:

Our survey showed a high satisfaction degree with apatinib in long-term cancer survivors. Long-term apatinib treatment resulted in almost no negative impact on patient's quality of life.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piridinas / Medición de Resultados Informados por el Paciente / Supervivientes de Cáncer / Trastornos del Inicio y del Mantenimiento del Sueño / Neoplasias Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piridinas / Medición de Resultados Informados por el Paciente / Supervivientes de Cáncer / Trastornos del Inicio y del Mantenimiento del Sueño / Neoplasias Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido